RMD ResMed Inc.

Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

Earnings webcast details:

 Location:
 Date:Wednesday, April 23, 2025
 Time:1:30 p.m. PDT / 4:30 p.m. EDT
 International:London, Wednesday, April 23, 2025, 9:30 p.m. BST
   Sydney, Thursday, April 24, 2025, 6:30 a.m. AEST



Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.

A replay of the earnings webcast will be accessible on Resmed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from April 23, 2025, until May 7, 2025, at:

 U.S.: +1 877.660.6853
 International: +1 201.612.7415
 Conference ID: 13752711



About Resmed


Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

For investors

For media

+1 858.836.5000+1 619.510.1281
  


EN
02/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE

Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, ...

Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US FDA-cleared home sleep test provides an effective and simplified solution to obstructive sleep apnea testing and diagnosis SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, ™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified,...

 PRESS RELEASE

Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025 SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location: •Date:Wednesday, April 23, 2025 •Time:1:30 p.m. PD...

 PRESS RELEASE

New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of dying by 37% and the chance of heart-related death by 55%. SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in , demonstrating that CPAP t...

 PRESS RELEASE

Resmed Unveils Unified Brand to Lead the Global Sleep and Health Techn...

Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution Brand Evolution Unites Brands Under One Resmed Identity to Make Better Sleep and Breathing Health More Accessible to Everyone SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement. For 35 year...

ResMed Inc: 1 director

A director at ResMed Inc sold 2,000 shares at 227.710USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch